Altimmune Inc (ALT)
7.15
-0.05
(-0.69%)
USD |
NASDAQ |
Apr 26, 12:00
Altimmune Revenue (Quarterly): 0.037M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.037M |
| September 30, 2023 | 0.362M |
| June 30, 2023 | 0.006M |
| March 31, 2023 | 0.021M |
| December 31, 2022 | -0.11M |
| September 30, 2022 | 0.002M |
| June 30, 2022 | 0.008M |
| March 31, 2022 | 0.032M |
| December 31, 2021 | 3.277M |
| September 30, 2021 | 0.158M |
| June 30, 2021 | 0.137M |
| March 31, 2021 | 0.838M |
| December 31, 2020 | 2.313M |
| September 30, 2020 | 2.938M |
| June 30, 2020 | 0.7216M |
| March 31, 2020 | 2.213M |
| December 31, 2019 | 0.5758M |
| September 30, 2019 | 0.644M |
| June 30, 2019 | 1.626M |
| March 31, 2019 | 2.956M |
| December 31, 2018 | 2.589M |
| September 30, 2018 | 2.634M |
| June 30, 2018 | 2.417M |
| March 31, 2018 | 2.691M |
| December 31, 2017 | 10.70M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.0267M |
| June 30, 2017 | 0.0049M |
| March 31, 2017 | 0.0049M |
| December 31, 2016 | 0.2418M |
| September 30, 2016 | 0.0049M |
| June 30, 2016 | 0.1585M |
| March 31, 2016 | 1.006M |
| December 31, 2015 | 1.266M |
| September 30, 2015 | 1.156M |
| June 30, 2015 | 1.150M |
| March 31, 2015 | 7.069M |
| December 31, 2014 | 1.826M |
| September 30, 2014 | 0.9625M |
| June 30, 2014 | 3.659M |
| March 31, 2014 | 3.742M |
| December 31, 2013 | 3.654M |
| September 30, 2013 | 3.488M |
| June 30, 2013 | 4.295M |
| March 31, 2013 | 6.475M |
| December 31, 2012 | 6.014M |
| September 30, 2012 | 6.696M |
| June 30, 2012 | 6.317M |
| March 31, 2012 | 6.149M |
| December 31, 2011 | 6.240M |
| September 30, 2011 | 5.260M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-0.11M
Minimum
Dec 2022
3.277M
Maximum
Dec 2021
0.8315M
Average
0.362M
Median
Sep 2023
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 9.353B |
| Amgen Inc | 8.196B |
| Viking Therapeutics Inc | -- |
| Precision BioSciences Inc | 7.038M |
| Terns Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -31.64M |
| Total Expenses (Quarterly) | 21.24M |
| EPS Diluted (Quarterly) | -0.56 |
| Enterprise Value | 312.63M |
| Profit Margin (Quarterly) | -85.52K% |
| Earnings Yield | -23.36% |
| Normalized Earnings Yield | -23.36 |